Etidronate disodium

Modify Date: 2024-01-09 14:31:37

Etidronate disodium Structure
Etidronate disodium structure
Common Name Etidronate disodium
CAS Number 7414-83-7 Molecular Weight 249.992
Density N/A Boiling Point 578.8ºC at 760 mmHg
Molecular Formula C2H6Na2O7P2 Melting Point > 300ºC
MSDS Chinese USA Flash Point 303.8ºC
Symbol GHS07
GHS07
Signal Word Warning

 Use of Etidronate disodium


Etidronic acid (Etidronate) disodium is an orally and intravenously active bisphosphonate. Etidronic acid disodium inhibits resorption of bone, reduces arterial calcification and can be used for osteoporosis research. Etidronic acid disodium has anticancer activity. Etidronic acid disodium is a chelating agent and can be used to remove heavy metal in water[1][2][3][4].

 Names

Name etidronate disodium
Synonym More Synonyms

 Etidronate disodium Biological Activity

Description Etidronic acid (Etidronate) disodium is an orally and intravenously active bisphosphonate. Etidronic acid disodium inhibits resorption of bone, reduces arterial calcification and can be used for osteoporosis research. Etidronic acid disodium has anticancer activity. Etidronic acid disodium is a chelating agent and can be used to remove heavy metal in water[1][2][3][4].
Related Catalog
In Vitro Etidronic acid (Etidronate) (10 mM, 24 h) disodium shows cytotoxicity, causes a decrease in the S-phase population and an increase in the G2/M population, induces p53 mutation in MCF-7 cells[3]. Etidronic acid (100 nM, 24 h) disodium induces osteoclast apoptosis, which displays characteristics of apoptosis, including chromatin condensation and changed cellular and nuclear morphology, detected by fluorescence microscopy[5].
References

[1]. Dunn CJ, et al. Etidronic acid. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs Aging. 1994 Dec;5(6):446-74.

[2]. Ariyoshi T, et al. Effect of etidronic acid on arterial calcification in dialysis patients. Clin Drug Investig. 2006;26(4):215-22.

[3]. Zhou Y, et al. Cytotoxicity of etidronic acid to human breast cancer cells. Ethn Dis. 2008 Spring;18(2 Suppl 2):S2-87-92.

[4]. Zhu S, et al. In-Depth Study of Heavy Metal Removal by an Etidronic Acid-Functionalized Layered Double Hydroxide. ACS Appl Mater Interfaces. 2022 Feb 9;14(5):7450-7463.

[5]. Kameda T, et al. Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts. J Exp Med. 1997 Aug 18;186(4):489-95.

 Chemical & Physical Properties

Boiling Point 578.8ºC at 760 mmHg
Melting Point > 300ºC
Molecular Formula C2H6Na2O7P2
Molecular Weight 249.992
Flash Point 303.8ºC
Exact Mass 249.938416
PSA 160.57000
Storage condition 2-8°C
Water Solubility H2O: 26 mg/mL | Soluble in water (26 mg/ml).

 Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
SZ8562240
CHEMICAL NAME :
Phosphonic acid, (1-hydroxyethylidene)di-, disodium salt
CAS REGISTRY NUMBER :
7414-83-7
LAST UPDATED :
199806
DATA ITEMS CITED :
22
MOLECULAR FORMULA :
C2-H6-O7-P2.2Na
MOLECULAR WEIGHT :
250.00
WISWESSER LINE NOTATION :
QPQOYQ1OPQQ &-NA- 2

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
588 mg/kg/28W-I
TOXIC EFFECTS :
Musculoskeletal - osteomalacia Musculoskeletal - other changes
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
1340 mg/kg
TOXIC EFFECTS :
Kidney, Ureter, Bladder - changes in both tubules and glomeruli
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
372 mg/kg
TOXIC EFFECTS :
Sense Organs and Special Senses (Eye) - chromodacryorrhea Sense Organs and Special Senses (Eye) - ptosis Behavioral - somnolence (general depressed activity)
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
73 mg/kg
TOXIC EFFECTS :
Sense Organs and Special Senses (Eye) - ptosis Behavioral - convulsions or effect on seizure threshold Kidney, Ureter, Bladder - other changes
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
1900 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
260 mg/kg
TOXIC EFFECTS :
Behavioral - altered sleep time (including change in righting reflex) Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - dyspnea
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
49 mg/kg
TOXIC EFFECTS :
Peripheral Nerve and Sensation - flaccid paralysis without anesthesia (usually neuromuscular blockage) Behavioral - altered sleep time (including change in righting reflex) Behavioral - convulsions or effect on seizure threshold
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
500 mg/kg
TOXIC EFFECTS :
Sense Organs and Special Senses (Eye) - mydriasis (pupillary dilation) Behavioral - ataxia Gastrointestinal - nausea or vomiting
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
32 mg/kg
TOXIC EFFECTS :
Cardiac - arrhythmias (including changes in conduction) Cardiac - pulse rate increase, without fall in BP Lungs, Thorax, or Respiration - dyspnea
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rabbit
DOSE/DURATION :
581 mg/kg
TOXIC EFFECTS :
Gastrointestinal - hypermotility, diarrhea Kidney, Ureter, Bladder - interstitial nephritis
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
72800 mg/kg/26W-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - changes in both tubules and glomeruli Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Nutritional and Gross Metabolic - changes in calcium
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
14560 mg/kg/13W-C
TOXIC EFFECTS :
Endocrine - other changes Blood - other changes Related to Chronic Data - death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
14560 mg/kg/52W-I
TOXIC EFFECTS :
Behavioral - ataxia Kidney, Ureter, Bladder - changes in bladder weight Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - phosphokinase
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
2500 mg/kg
SEX/DURATION :
female 6-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Effects on Newborn - live birth index (measured after birth)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
5500 mg/kg
SEX/DURATION :
female 1-22 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - other measures of fertility
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
86 gm/kg
SEX/DURATION :
male 9 week(s) pre-mating female 2 week(s) pre-mating female 1-7 day(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - other effects Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
11 gm/kg
SEX/DURATION :
female 7-17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - other effects Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Effects on Newborn - live birth index (measured after birth)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
7800 mg/kg
SEX/DURATION :
female 17-22 day(s) after conception lactating female 20 day(s) post-birth
TOXIC EFFECTS :
Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive) Reproductive - Effects on Newborn - physical
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
1500 ug/kg
SEX/DURATION :
female 2-16 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

MUTATION DATA

TYPE OF TEST :
Cytogenetic analysis
TEST SYSTEM :
Rodent - hamster Ovary
DOSE/DURATION :
1 mmol/L
REFERENCE :
KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 23,1343,1989 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X2888 No. of Facilities: 78 (estimated) No. of Industries: 2 No. of Occupations: 2 No. of Employees: 1099 (estimated)

 Safety Information

Symbol GHS07
GHS07
Signal Word Warning
Hazard Statements H302
Precautionary Statements P301 + P312 + P330
Hazard Codes Xn
Risk Phrases R22
Safety Phrases 36/37/39
RIDADR NONH for all modes of transport
WGK Germany 1
RTECS SZ8562240

 Articles6

More Articles
Effects of various squalene epoxides on coenzyme Q and cholesterol synthesis.

Biochim. Biophys. Acta 1841(7) , 977-86, (2014)

2,3-Oxidosqualene is an intermediate in cholesterol biosynthesis and 2,3:22,23-dioxidosqualene act as the substrate for an alternative pathway that produces 24(S),25-epoxycholesterol which effects cho...

Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.

Lancet Oncol. 15(13) , 1460-8, (2014)

Aromatase inhibitors prevent breast cancer in postmenopausal women at high risk of the disease but are associated with accelerated bone loss. We assessed effectiveness of oral risedronate for preventi...

A novel automated hydrophilic interaction liquid chromatography method using diode-array detector/electrospray ionization tandem mass spectrometry for analysis of sodium risedronate and related degradation products in pharmaceuticals

J. Chromatogr. A. 1365 , 131-9, (2014)

• HPLC fused core technology to analyze SR and its degradation products. • Stress test studies on raw material, finished products and placebos. • No interference of the complex matrices (new pharmaceu...

 Synonyms

Disodium (1-hydroxy-1,1-ethanediyl)bis[hydrogen (phosphonate)]
EINECS 231-025-7
Disodium Etidronate Hydrate
MFCD00152567
Didronel
Dinatrium-(1-hydroxyethan-1,1-diyl)bis[hydrogen-(phosphonat)]
1-Hydroxyethylidene-1,1-diphosphonic acid disodium salt
Etidronate disodium
Disodium (1-hydroxyethane-1,1-diyl)bis[hydrogen (phosphonate)]
Phosphonic acid, (1-hydroxyethylidene)bis-, sodium salt (1:2)
disodium etidronate
Disodium (1-hydroxyethylidene)diphosphonate
disodium,hydroxy-[1-hydroxy-1-[hydroxy(oxido)phosphoryl]ethyl]phosphinate
Disodium 1-hydroxyethylidene phosphonate
(1-Hydroxyethylidene)diphosphonic acid, disodium salt
(1-hydroxyéthane-1,1-diyl)bis[hydrogène (phosphonate)] de disodium
Top Suppliers:I want be here






Get all suppliers and price by the below link:

Etidronate disodium suppliers

Etidronate disodium price